IP Library › Granted Patent US 11,448,641
Granted Patent B2
US 11,448,641 · App. 16/203,336 · Granted Sep 20, 2022

Methods and devices for separation of blood components

Inventors: Nabil Mikhaiel (Newport News, VA); Lindsay Sanford (Coventry, CT); Kelly Coughenour (Newport News, VA); Jeremy Schreiber (Newport News, VA)
Assignee: Canon Virginia, Inc.
G01N33/5002A61M1/029A61M1/0259B01D17/0214B01D21/286B04B5/0442B04B13/00A61M2202/0415
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,448,641
App. No.
16/203,336
Granted
Sep 20, 2022
Kind
B2
Abstract

The present disclosure relates to methods and devices for the separation of blood components including separation by rapid sedimentation, including in an automated fashion.

Claims (24)

1. A method of accelerating the non-centrifugal separation of blood components from a sample, wherein the method comprises the steps of:

(i) providing the sample in a vessel;

(ii) mixing the sample with one or more aggregating agents to form a mixture, wherein the one or more aggregating agents comprise an acute phase protein;

(iii) incubating the mixture;

(iv) inclining the vessel during incubation; and

(v) collecting one or more of the blood components, wherein one of the one or more blood components is plasma.

2. The method of claim 1 , wherein the collected plasma contains circulating cell-free DNA.

3. The method of claim 1 , wherein step (iv) additionally comprises exposing the mixture to one or more of a mechanical or physical aggregation means selected from the group consisting of:

a. vibration;

b. heating;

c. tapping; and,

d. exposure to an electromagnetic field.

4. The method of claim 1 , wherein the one or more aggregating agents comprise fibrinogen.

5. The method of claim 4 , wherein the fibrinogen is at a concentration of from 5 to 50 mg/ml.

6. The method of claim 5 , wherein the fibrinogen is at a concentration of 30 mg/ml.

7. The method of claim 4 , wherein the method additionally comprises tapping the vessel while the vessel is inclined.

8. The method of claim 7 , wherein the tapping of the vessel occurs for 10 minutes, and the incline is at 45°.

9. The method of claim 1 , wherein the sample comprises whole blood.

10. A method of accelerating the non-centrifugal separation of blood components from a sample, wherein at least one of the components is plasma containing circulating cell-free DNA, wherein the method comprises the steps of:

(i) providing the sample in a vessel;

(ii) mixing the sample with one or more aggregating agents to form a mixture, wherein the one or more aggregating agents comprise a macromolecule;

(iii) incubating the mixture; and

(iv) inclining the vessel during incubation.

11. The method of claim 10 , wherein the one or more aggregating agents are selected from the group consisting of Fibrinogen, Dextran, Hydroxyethyl Starch (HES), Polyvinylpyyrolidone (PVP), Polyethylene Glycol (PEG), and Gelatin.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 9, 2022
From: MIKHAIEL, NABIL; SANFORD, LINDSAY; COUGHENOUR, KELLY; SCHREIBER, JEREMY
To: CANON VIRGINIA, INC.
Reel/Frame 060758/0034 →
Continuity (2)
Provisional Application 62591761 · Nov 28, 2017
Related Publication 20190162716A1 · May 30, 2019
Cited By (1)
US 12,298,296